VERAXA Biotech GmbH

Booth 1239
Heidelberg, Germany
VERAXA is an early-stage biotechnology company with game-changing antibody discovery, screening and conjugation technology yielding the most optimized Antibody Drug Conjugates (ADCs) at scale.

We are looking for partners or collaborators to license / co-develop:

our internal pipeline of ADCs which are optimized for internalization and toxicity.

our click-chemistry technology for side-specific conjugation and the generation of ADCs with a highly precise drug-to-antibody ratio and improved PK/PD.

novel functional antibodies using our one-step microfluidic screening platform.

We are not looking to provide these services as a contract research organization, we are looking for partners to co-develop the best ADCs possible and bring them into the clinic.

With our proprietary high throughput droplet-based microfluidic platform, we can screen entire immune repertoires containing millions of antibody-secreting cells for binding, functionality, and internalization in one step, on a single-cell level. Our unique ADC technology utilizes genetic code expansion and bioorthogonal click chemistry to precisely and efficiently conjugate payloads at freely selectable antibody sites.